Cleara Biotech B.V.

About Cleara Biotech B.V.

Cleara Biotech is a biopharmaceutical research and development (R&D) company focused on developing peptide-based therapies against cancer and chronic diseases. Our lead program focuses on generating compounds against cancer cells with high levels of impaired-p53 signaling, especially those with mutant p53. Over two decades of fundamental research led to an understanding of how p53 signaling becomes impaired in cells suffering from irreparable damage. This proved to be a vulnerability that could be exploited to develop therapeutics against these diseases. Using this proprietary knowledge, Cleara Biotech developed a disruptive, innovative platform technology to safely and selectively eliminate p53-impaired cells. This resulted in a development candidate, CL04183, which selectively induces apoptosis in cancer cells harboring impaired p53 in ways that are (1) not transcription-dependent and (2) agnostic of the mutation site.